Circulating programmed death-1 as a marker for sustained high hepatitis b viral load and risk of hepatocellular carcinoma e95870

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Cheng, Hsiang Yun ^a   Kang, Pei Jen ^a   Chuang, Ya Hui ^b   Wang, Ya Hui ^a   Jan, Meng Chin ^a   Wu, Chih Feng ^a   Lin, Chih Lin ^c   Liu, Chun Jen ^d   Liaw, Yun Fan ^e   Lin, Shi Ming ^e   Chen, Pei Jer ^d   Lee, Shou Dong ^f,g   Yu, Ming Whei ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c TAIPEI CITY HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^f TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^g CHENG HSIN GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; HEPATITIS B SURFACE ANTIGEN; PROGRAMMED DEATH 1 RECEPTOR; PDCD1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; HEPATITIS B; HEPATITIS B VIRUS GENOTYPE B; HEPATITIS B VIRUS GENOTYPE C; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; ONSET AGE; VIRUS LOAD; BLOOD; CARCINOMA, HEPATOCELLULAR; CASE CONTROL STUDY; COMPLICATION; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; ISOLATION AND PURIFICATION; LIVER NEOPLASMS; MIDDLE AGED; PHYSIOLOGY; RISK FACTOR; VIROLOGY;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; COHORT STUDIES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; RISK FACTORS; VIRAL LOAD;

EID: 84983724143     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095870     Document Type: Article

References (33)

1. Sanyal AJ, Yoon SK, Lencioni R (2010) The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist 15 (Suppl 4): 14-22.
2. Yu MW, Yeh SH, Chen PJ, Liaw YF, Lin CL, et al. (2005) Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 97: 265-272.
3. Wu CF, Yu MW, Lin CL, Liu CJ, Shih WL, et al. (2008) Long-term tracking of hepatitis B viral load and the relationship with risk for hepatocellular carcinoma in men. Carcinogenesis 29: 106-112.
4. Chan HL, Tse CH, Mo F, Koh J, Wong VW, et al. (2008) High viral load and hepatitis B virus subgenotype Ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol 26: 177-182.
5. Huang CJ, Wu CF, Lan CY, Sung FY, Lin CL, et al. (2013) Impact of Genetic heterogeneity in polymerase of hepatitis B virus on dynamics of viral load and hepatitis B progression. PLoS One 8: e70169.
6. Thompson A, Locarnini S, Visvanathan K (2007) The natural history and the staging of chronic hepatitis B: time for reevaluation of the virus-host relationship based on molecular virology and immunopathogenesis considerations? Gastroenterology 133: 1031-1035.
7. Dandri M, Locarnini S (2012) New insight in the pathobiology of hepatitis B virus infection. Gut 61 (Suppl 1): i6-17.
8. Streeck H, Brumme ZL, Anastario M, Cohen KW, Jolin JS, et al. (2008) Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cells. PLoS Med 5: e100.
9. Fisicaro P, Valdatta C, Massari M, Loggi E, Biasini E, et al. (2010) Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 138: 682-693.
10. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, et al. (2006) Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439: 682-687.
11. Velu V, Titanji K, Zhu B, Husain S, Pladevega A, et al. (2009) Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 458: 206-210.
12. Evans A, Riva A, Cooksley H, Phillips S, Puranik S, et al. (2008) Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion. Hepatology 48: 759-769.
13. Shi F, Shi M, Zeng Z, Qi RZ, Liu ZW, et al. (2011) PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer 128: 887-896.
14. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, et al. (2009) Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114: 1537-1544.
15. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, et al. (2010) Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 207: 2187-2194.
16. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, et al. (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 99: 12293-12297.
17. Wan B, Nie H, Liu A, Feng G, He D, et al. (2006) Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J Immunol 177: 8844-8850.
18. Xiao H, Huang B, Yuan Y, Li D, Han LF, et al. (2007) Soluble PD-1 facilitates 4-1BBL-triggered antitumor immunity against murine H22 hepatocarcinoma in vivo. Clin Cancer Res 13: 1823-1830.
19. Rose-John S, Heinrich PC (1994) Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J 300: 281-290.
20. Heaney ML, Golde DW (1998) Soluble receptors in human disease. J Leukoc Biol 64: 135-146.
21. Yu MW, Shih WL, Lin CL, Liu CJ, Jian JW, et al. (2008) Body-mass index and progression of hepatitis B: a population-based cohort study in men. J Clin Oncol 26: 5576-5582.
22. Shih WL, Chang HC, Liaw YF, Lin SM, Lee SD, et al. (2012) Influences of tobacco and alcohol use on hepatocellular carcinoma survival. Int J Cancer 131: 2612-2621.
23. Andersson T, Alfredsson L, Källberg H, Zdravkovic S, Ahlbom A (2005) Calculating measures of biological interaction. Eur J Epidemiol 20: 575-579.
24. Nguyen LH, Ko S, Wong SS, Tran PS, Trinh HN, et al. (2011) Ethnic differences in viral dominance patterns in patients with hepatitis B virus and hepatitis C virus dual infection. Hepatology 53: 1839-1845.
25. Nakamoto N, Kaplan DE, Coleclough J, Li Y, Valiga ME, et al. (2008) Functional restoration of HCVspecific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization. Gastroenterology 134: 1927-1937.
26. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, et al. (2008) Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2: 263-283.
27. Sung FY, Jung CM, Wu CF, Lin CL, Liu CJ, et al. (2009) Hepatitis B virus core variants modify natural course of viral infection and hepatocellular carcinoma progression. Gastroenterology 137: 1687-1697.
28. Desmond CP, Bartholomeusz A, Gaudieri S, Revill PA, Lewin SR (2008) A systematic review of T-cell epitopes in hepatitis B virus: identification, genotypic variation and relevance to antiviral therapeutics. Antivir Ther 13: 161-175.
29. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, et al. (2006) PD-1 expression on HIVspecific T cells is associated with T-cell exhaustion and disease progression. Nature 443: 350-354.
30. Yu MW, Chen CJ (1994) Hepatitis B and C viruses in the development of hepatocellular carcinoma. Crit Rev Oncol Hematol 17: 71-91.
31. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, et al. (2007) Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317: 121-124.
32. Ury HK (1975) Efficiency of case-control studies with multiple controls per case: continuous or dichotomous data. Biometrics 31: 643-649.
33. Perel P, Roberts I, Sena E, Wheble P, Briscoe C, et al. (2007) Comparison of treatment effects between animal experiments and clinical trials: systematic review. BMJ 334: 197.